Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Savoye · SciRah

Researcher profile · Semantic Scholar

A. Savoye

Share profile

A. Savoye — researcher profile on SciRah

h-index: 13
Works: 59
Citations: 635

Most-cited papers

IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2
Stéphanie Cochaud, J. Giustiniani, Clémence Thomas, E. Laprévotte +9 more
2013Scientific Reports135 citations Open access
Semantic Scholar
Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial.
C. Falandry, B. Weber, A. Savoye, F. Tinquaut +8 more
2013Annals of Oncology116 citations Open access
Semantic Scholar
Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A Randomized Clinical Trial.
C. Falandry, F. Rousseau, M. Mouret-Reynier, F. Tinquaut +16 more
2021JAMA Oncology60 citations Open access
Semantic Scholar
Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study.
F. Joly, D. Ahmed-Lecheheb, E. Kalbacher, N. Heutte +26 more
2019Annals of Oncology54 citations Open access
Semantic Scholar
EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study.
C. Falandry, A. Savoye, L. Stefani, F. Tinquaut +16 more
2019Journal of Clinical Oncology27 citations
Semantic Scholar
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial
I. Ray-Coquard, A. Savoye, C. Schiffler, M. Mouret-Reynier +20 more
2024Nature Communications26 citations Open access
Semantic Scholar
Final results from a phase III randomized clinical trial of adjuvant endocrine therapy ± chemotherapy in women ≥ 70 years old with ER+ HER2- breast cancer and a high genomic grade index: The Unicancer ASTER 70s trial.
E. Brain, A. Viansone, E. Bourbouloux, O. Rigal +16 more
2022Journal of Clinical Oncology23 citations
Semantic Scholar
Impact of Chemotherapy‐induced Menopause in Women of Childbearing Age With Non‐metastatic Breast Cancer – Preliminary Results From the MENOCOR Study
J. Passildas, O. Collard, A. Savoye, Joyce Dohou +7 more
2019Clinical Breast Cancer20 citations Open access
Semantic Scholar
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma
O. Le Saux, M. Ardin, Justine Berthet, S. Barrin +24 more
2024Nature Communications18 citations Open access
Semantic Scholar
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial.
E. Brain, O. Mir, E. Bourbouloux, O. Rigal +18 more
2025The Lancet17 citations Open access
Semantic Scholar
In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study.
I. Ray-Coquard, M. Kaminsky-Forrett, Ryotaro Ohkuma, A. de Montfort +15 more
2023Journal of Clinical Oncology15 citations Open access
Semantic Scholar
Adjustment of young women with breast cancer after chemotherapy: A mediation model of emotional competence via emotional distress
Anne-Sophie Baudry, Sonya Yakimova, A. Congard, A. Untas +10 more
2022Psycho-Oncology14 citations Open access
Semantic Scholar
Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients
D. Berton, A. Floquet, W. Lescaut, G. Baron +17 more
2021Frontiers in Pharmacology13 citations Open access
Semantic Scholar
PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207).
J. Huober, P. Weder, C. Veyret, B. Thürlimann +15 more
2018Annals of Oncology11 citations Open access
Semantic Scholar
“Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors”
F. Gernier, D. Ahmed-Lecheheb, P. Pautier, A. Floquet +23 more
2021BMC Cancer9 citations Open access
Semantic Scholar
First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study
A. Hardy-Bessard, F. Brocard, F. Clatot, A. Lortholary +11 more
2020Breast9 citations Open access
Semantic Scholar
727P Phase Ib INEOV neoadjuvant trial of the anti-PDL1, durvalumab (D) +/- anti-CTLA4 tremelimumab (T) with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): A GINECO study
A. Leary, T. de la Motte Rouge, A. Lortholary, B. Asselain +11 more
2021Annals of Oncology8 citations Open access
Semantic Scholar
Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database.
A. de Nonneville, C. Zemmour, S. Frank, F. Joly +20 more
2021Gynecologic Oncology8 citations Open access
Semantic Scholar
Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial
I. Ray-Coquard, M. Kaminsky-Forrett, Ryotaro Ohkuma, A. de Montfort +20 more
2026Nature Communications6 citations Open access
Semantic Scholar
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
J. Huober, P. Weder, K. Ribi, B. Thürlimann +17 more
2023JAMA Oncology6 citations Open access
Semantic Scholar
Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas
Ondine Becker, A. Durand, M. Chevrier, Laetitia Collet +22 more
2024International Journal of Gynecological Cancer5 citations Open access
Semantic Scholar
Phase Ib INEOV neoadjuvant trial of durvalumab +/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): Survival outcomes and immune correlates.
A. Leary, Laure Chardin, Alain Lortholary, B. Asselain +12 more
2024Journal of Clinical Oncology5 citations Open access
Semantic Scholar
The COVID-19 pandemic did not adversely affect clinical trial enrollment in gynecologic oncology trials at a single academic institution
O. Trédan, M. Provansal, C. Abdeddaim, Audrey Lardy-Cleaud +22 more
2021Gynecologic Oncology5 citations Open access
Semantic Scholar
Everolimus-induced pulmonary toxicity
S. Dejust, D. Morland, C. Bruna-Muraille, J. Eymard +3 more
2018Medicine5 citations Open access
Semantic Scholar
Is it important to adapt neoadjuvant chemotherapy to the visible clinical response? An open randomized phase II study comparing response-guided and standard treatments in HER2-negative operable breast cancer.
Q. Wang-Lopez, M. Mouret-Reynier, A. Savoye, C. Abrial +9 more
2015The Oncologist4 citations Open access
Semantic Scholar
Phase Ib INEOV neoadjuvant trial of durvalumab +/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): Final complete resection and pathological response rates.
A. Leary, T. de la Motte Rouge, A. Lortholary, B. Asselain +11 more
2022Journal of Clinical Oncology3 citations
Semantic Scholar
Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database
M. Bini, S. Quesada, P. Meeus, M. Rodrigues +21 more
2022Cancers3 citations Open access
Semantic Scholar
Dynamic Prediction of Resectability for Patients with Advanced Ovarian Cancer Undergoing Neo-Adjuvant Chemotherapy: Application of Joint Model for Longitudinal CA-125 Levels
K. Amroun, R. Chaltiel, F. Reyal, R. Kianmanesh +4 more
2022Cancers2 citations Open access
Semantic Scholar
Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry.
J. Michels, C. Genestie, A. Dunant, O. Caron +13 more
2020Gynecologic Oncology2 citations
Semantic Scholar
Use of bevacizumab (Bev) in real life for first-line (fl) treatment of ovarian cancer (OC)/ The GINECO ENCOURAGE cohort of 500 French patients
D. Berton-Rigaud, A. Floquet, D. Mollon-Grange, A. Dechartres +16 more
2019Annals of Oncology2 citations Open access
Semantic Scholar
2022-RA-1551-ESGO Impact of age on first line treatments of ovarian cancer and their outcomes: results from the Unicancer ESME OVR real-world database
L. Lefevre, Anaïs Fouquier, I. Ray-Coquard, L. Favier +17 more
2022Ovarian cancer1 citations Open access
Semantic Scholar
2022-RA-276-ESGO Value of surgical cytoreduction for subsequent ovarian cancer relapse in patients previously treated with chemotherapy alone at 1st-relapse: a subanalysis of the DESKTOP III/ENGOT-ov20 trial
C. Fotopoulou, J. Sehouli, I. Vergote, A. Reuss +16 more
2022Ovarian cancer1 citations Open access
Semantic Scholar
746P Real-world clinical outcomes of patients with de novo advanced high-grade epithelial ovarian cancer eligible to niraparib maintenance in France
M. Rodrigues, F. Joly, I. Ray-Coquard, H. Costaz +16 more
2021Annals of Oncology1 citations Open access
Semantic Scholar
829P Regorafenib (R) or tamoxifen (T) for platinum-sensitive recurrent ovarian cancer (PSROC) with rising CA125 and no evidence of clinical or radiological disease progression: A GINECO randomized phase II trial
O. Tredan, M. Gross, C. Abdeddaim, S. Chabaud +16 more
20201 citations Open access
Semantic Scholar
Abstract PS2-09-14: When interception needs a second chance: ctDNA dynamics in ER+/HER2- advanced breast cancer treated with 1st line CDK4/6 inhibitors - Insights from the CICLADES study
V. Massard, M. Betz, A. Diallo, J. Salleron +12 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Clinical outcomes and prognostic factors in advanced high-grade platinum-resistant ovarian carcinoma: evidence from the ESME real-world cancer database.
V. Heurtier, P. Macouillard, I. Ray-Coquard, R. Sabatier +18 more
2026International Journal of Gynecological Cancer0 citations
Semantic Scholar
Role of surgery in stage IV high-grade serous ovarian cancer: a French population-based multi-center study using Epidemiological Strategy and Medical Economics ovarian cancer database.
Diana Bello Roufai, M. Chevrier, L. Gladieff, H. Costaz +16 more
2026International Journal of Gynecological Cancer0 citations
Semantic Scholar
The impact of chemotherapy-induced menopause on quality of life 30 months following treatment among young women with non-metastatic breast cancer: results from the prospective multicentre MENOCOR clinical trial
Mélanie Godiveau, A. Giró, J. Passildas, J. Jacquin +5 more
2026Health and Quality of Life Outcomes0 citations Open access
Semantic Scholar
Abstract PS2-04-25: Efficacy of maintenance endocrine therapy combined with trastuzumab + pertuzumab following taxane induction in HR+/HER2+ metastatic breast cancer: A real-world reproduction of the PATINA trial control arm
L. Mathiot, A. Lusque, T. Grinda, T. Petit +15 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Abstract P3-08-03: Trends in Presentation of HER2+ Breast Cancer: A Retrospective study of De Novo Versus Recurrent Metastatic Breast Cancer (MBC) in the Real-World French National ESME Cohort (2008-2022)
T. Grinda, A. Lusque, S. Morganti, D. Pasquier +21 more
2025Clinical Cancer Research0 citations
Semantic Scholar
Metastatic sites and surgical management in stage IV ovarian cancer: Is there a place for debulking surgery in FIGO stage IVB patients? A retrospective study from the ESME national cohort
Navid Mokarram Dorri, Laura Foulhioux, C. Zemmour, Q. Thomas +16 more
2025Clinical Surgical Oncology0 citations Open access
Semantic Scholar
Surgical approach and maintenance therapy in advanced low-grade serous ovarian cancer: Insights from the French ESME database.
T. Papazyan, Elodie Martin, Patricia Pautier, C. Guérin-Charbonnel +17 more
2025International Journal of Gynecological Cancer0 citations
Semantic Scholar
856 Routine baseline blood tests predicting pembrolizumab sensitivity in advanced high-grade serous ovarian cancer (AHGSOC) 1st line therapy: substudy from the NEOPEMBROV/GINECO (NCT03275506) randomized trial
S. Quesada, I. Ray-Coquard, C. Schiffler, A. Savoye +16 more
2024Poster and E-Posters0 citations Open access
Semantic Scholar
Abstract PO3-05-02: Impact of hormone receptor expression level in HR+/HER2- metastatic breast cancer in the large French ESME cohort
Marie Alexandre, F. Castan, T. de la Motte Rouge, A. Mailliez +16 more
2024Cancer Research0 citations
Semantic Scholar
Immune features of ovarian tumors with a good response to neo-adjuvant chemotherapy in combination with an anti-PD-L1 alone or with an anti-CTLA4: Data from the randomized IneOV trial (a GINECO study).
A. Leary, Laure Chardin, C. Genestie, A. Lortholary +10 more
2023Journal of Clinical Oncology0 citations Open access
Semantic Scholar
2022-RA-1088-ESGO Chitinase response after 3 cycles of chemotherapy as a promising marker of chemosensitivity an ancillary analysis of the GINECO-ENGOT EWOC-1 trial
K. Chikh, C. Cuerq, M. Valero, O. Colomban +15 more
2022Ovarian cancer0 citations Open access
Semantic Scholar
Abstract 1022: Disparities in accessibility to oncology care centers in France
Eric Daoud, A. Hamy, Elise Dumas, Lidia Delrieu +10 more
2022Cancer Research0 citations
Semantic Scholar
2022-RA-823-ESGO FOXL2 mutation detection in circulating tumor DNA of adult granulosa cell tumors as a potential biomarker for disease monitoring from the randomized ALIENOR trial, a GINECO study
I. Treilleux, Alexandra Lainé, V. Combaret, C. Dalban +16 more
2022Ovarian cancer0 citations Open access
Semantic Scholar
2022-RA-1294-ESGO Chemosensitivity in vulnerable older patients is unfavorable and highly dependent on the treatment regimen: CA125 elimination rate constant K (KELIM) analysis of the GINECO-ENGOT EWOC-1 trial
O. Colomban, E. Bourbouloux, Marie-Ange Mouret-Renier, D. Lorusso +15 more
2022Ovarian cancer0 citations Open access
Semantic Scholar
Disparities in accessibility to oncology care centers in France
Eric Daoud, A. Hamy-Petit, Elise Dumas, L. Delrieu +10 more
2021medRxiv0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Floquet×15
Invite
A. Floquet — researcher profile on SciRah
T. de la Motte Rouge×13
Invite
T. de la Motte Rouge — researcher profile on SciRah
M. Mouret-Reynier×10
Invite
M. Mouret-Reynier — researcher profile on SciRah
A. Lortholary×9
Invite
A. Lortholary — researcher profile on SciRah

×9

Invite

I. Ray-Coquard — researcher profile on SciRah

Invite

L. Gladieff — researcher profile on SciRah

E. Pujade-Lauraine×8

Invite

E. Pujade-Lauraine — researcher profile on SciRah

Invite

V. D'Hondt — researcher profile on SciRah

L. Venat-Bouvet×8

Invite

L. Venat-Bouvet — researcher profile on SciRah

Invite

F. Joly — researcher profile on SciRah

Invite

P. Pautier — researcher profile on SciRah

Invite

J. Frenel — researcher profile on SciRah